Eli Lilly Agrees to Acquire Safeguard Scientifics Partner Company Avid Radiopharmaceuticals
For the second time in as many weeks, I am pleased to announce that a major player in the pharmaceutical industry has recognized the value…
Posted by
Safeguard Insights
Safeguard Scientifics and Partner Company Avid Radiopharmaceuticals Honored with Life Sciences Awards
Today, we were honored by the Philadelphia Business Journal with the Inaugural Life Sciences Venture Impact Award, which “goes to the venture capital firm from…
Posted by
Bloomberg Businessweek says Avid likely to Beat GE, Bayer to Market
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
New York Times puts Avid’s Technology Front and Center
Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights…
Posted by
Avid Radiopharmaceuticals Announces Positive Interim Results from Phase III Clinical Trial of Amyloid Imaging Agent Florbetapir F18
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by
Avid Radiopharmaceuticals Making Strides Toward Clinical Trial Milestone
I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…
Posted by
Avid Radiopharmaceuticals Presents at J.P. Morgan Investor Conference
Safeguard Scientifics’ partner company Avid Radiopharmaceuticals was invited to present its technology and growth strategy at the prestigious J.P. Morgan 28th Annual Healthcare Conference in…
Posted by
